# Co-administration of CART22-65s and huCART19 for B-ALL

> **NCT05674175** · PHASE1,PHASE2 · RECRUITING · sponsor: **Stephan Grupp MD PhD** · enrollment: 93 (estimated)

## Conditions studied

- B-cell Acute Lymphoblastic Leukemia
- B Lineage Lymphoblastic Lymphoma

## Interventions

- **BIOLOGICAL:** Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s)
- **BIOLOGICAL:** Autologous, humanized anti-CD19 CAR T cell therapy (huCART19)

## Key facts

- **NCT ID:** NCT05674175
- **Lead sponsor:** Stephan Grupp MD PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-01-25
- **Primary completion:** 2028-07-01
- **Final completion:** 2029-07-01
- **Target enrollment:** 93 (ESTIMATED)
- **Last updated:** 2026-03-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05674175

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05674175, "Co-administration of CART22-65s and huCART19 for B-ALL". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05674175. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*